SCHEMBL400139

SCHEMBL400139

c1n[nH]c2c1CCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10509 0.95
Hydrochloric Acid SCHEMBL30066525 0.93 KDR (0.41)
SCHEMBL29649189 0.93 KDR (0.41)
SCHEMBL4948667 0.93 KDR (0.41)
Hydrochloric Acid SCHEMBL30801293 0.93 KDR (0.41)
SCHEMBL31687184 0.93 KDR (0.41)
SCHEMBL31496664 0.93 KDR (0.41)
Hydrazine SCHEMBL6036676 0.89 DRD4 (0.40)
Oxalic Acid SCHEMBL572020 0.83 KDM4E (0.40)
SCHEMBL31665891 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505966-A4 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-08-30 EP claimed
EP-1505966-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 EP claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO claimed
EP-3721453-B1 THIN AND UNIFORM SILVER NANOWIRES, METHOD OF SYNTHESIS AND TRANSPARENT CONDUCTIVE FILMS FORMED FROM THE NANOWIRES EKC TECH INC (US) 2026-04-01 EP disclosed
EP-4663325-A2 THIN AND UNIFORM SILVER NANOWIRES, METHOD OF SYNTHESIS AND TRANSPARENT CONDUCTIVE FILMS FORMED FROM THE NANOWIRES EKC TECHNOLOGY, INC. (US) 2025-12-17 EP disclosed
WO-2025096653-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
WO-2025096658-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
WO-2025096662-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
US-20250084063-A1 BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS INCYTE CORPORATION 2025-03-13 US disclosed
WO-2025042736-A1 BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS INCYTE CORPORATION (US) 2025-02-27 WO disclosed
CN-118994114-A Pyrazolyl piperazinone compounds, pharmaceutical compositions and application thereof 睿健医药科技(苏州)有限公司 2024-11-22 CN disclosed
US-5362878-A Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) PFIZER INC. (US) 1994-11-08 US disclosed
EP-0609960-A1 New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase PFIZER INC. (US) 1994-08-10 EP disclosed
US-5049181-A Novel herbicidally active n-phenyl-azoles CIBA-GEIGY CORPORATION (US) 1991-09-17 US disclosed
WO-1991004027-A1 NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) PFIZER INC. (US) 1991-04-04 WO disclosed
EP-0418071-A2 New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase PFIZER INC. (US) 1991-03-20 EP disclosed
EP-0149487-B1 NEW CEPHEM COMPOUNDS, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-11-15 EP disclosed
US-4590186-A Cephem compounds having 3-bicyclic heterocyclic cation groups FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-05-20 US disclosed
EP-0149487-A2 New cephem compounds, process for preparation thereof and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-07-24 EP disclosed